Morbidity and mortality of nonagenarians undergoing CoreValve implantation

BMC Cardiovascular Disorders

Hüseyin Ince¹  Christoph A Nienaber¹  Ralf Birkemeyer¹  Jasmin Ortak¹  Ilkay Bozdag-Turan¹  Gunther Kundt²  Dimitar Divchev¹  Gökmen R Turan¹  Tim C Rehders¹  Henrik Schneider¹  Lylia Paranskaya¹  Stephan Kische¹  Ibrahim Akin¹ 

[1] Heart Center Rostock, Department of Internal Medicine I, University Hospital Rostock, Rostock School of Medicine, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany;Institute for Biostatistics and Information in Medicine and Ageing Research, Rostock School of Medicine, University Hospital Rostock, Ernst-Heydemann-Str 6, 18057, Rostock, Germany

关键词: TAVI;    Surgery;    Nonagenarian;    Aortic stenosis;    CoreValve;   

Others  :  1084371
DOI  :  10.1186/1471-2261-12-80

 received in 2012-04-16, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Background

Nonagenarians are mostly denied from different therapeutic strategies due to high comorbidity index and risk-benefit calculation. We present the results of nonagenarians with high comorbidity index not eligible for conventional aortic valve surgery undergoing transcatheter aortic valve implantation (TAVI) with the CoreValve system.

Methods

Our retrospective analysis include baseline parameters, procedural characteristics, morbidity, mortality as well as twelve-lead surface ECG and echocardiographic parameters which were revealed preinterventionally, at hospital discharge and at 30-day follow-up. Clinical follow-up was performed 6 months after TAVI.

Results

Out of 158 patients 11 nonagenarians with a mean age of 92.6 ± 1.3 years suffering from severe aortic valve stenosis and elevated comorbidity index (logistic EuroSCORE of 32.0 ± 9.5%, STS score 25.3 ± 9.7%) underwent TAVI between January 2008 and January 2011 using the third-generation percutaneous self-expanding CoreValve prosthesis. Baseline transthoracic echocardiography reported a mean aortic valve area (AVA) of 0.6 ± 0.2 cm² with a mean and peak pressure gradient of 60.2 ± 13.1mmHg and 91.0 ± 27.4mmHg, respectively. The 30-day follow up all cause and cardiovascular mortality was 27.3% and 9.1%, respectively. One major stroke (9.1%), 2 pulmonary embolisms (18.2%), 1 periprocedural (9.1%) and 1 (9.1%) spontaneous myocardial infarction occured. Life-threatening or disabling bleeding occurred in 2 cases (18.2%), and minor bleeding in 7 cases (63.6%). Mean severity of heart failure according to NYHA functional class improved from 3.2 ± 0.8 to 1.36 ± 0.5 while mean AVA increased from 0.6 ± 0.2cm² to 1.8 ± 0.2cm². At 6-months follow-up 8 patients (72.7%) were alive without any additional myocardial infarction, pulmonary embolism, bleeding, or stroke as compared to 30-day follow-up.

Conclusion

Our case series demonstrate that even with elevated comorbidity index, clinical endpoints and valve-associated results are relatively favorable in nonagenarians treated with CoreValve.

【 授权许可】

   
2012 Akin et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 52:e1-e142.
• [2]Varadarajan P, Kapoor N, Bansal RC, Pai RG: Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006, 82:2111-2115.
• [3]Cribrier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB: Percutaneous transcatheter implantation of an aortic valve prosthesis for calcified aortic stenosis: first human case description. Circulation 2002, 106:3006-3008.
• [4]Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribrier A, De Jaegere P, Fournial G, Kappetein AP, Kovac J, Ludgate S, Maisano F, Moat N, Mohr F, Nataf P, Pierard L, Pomar JL, Schofer J, Tornos P, Tuzcu M, van Hout B, von Segesser LK, Walther T, European Association of Cardio-Thoracic Surgery, European Association of Percutaneous Cardiovascular Interventions: Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Intervention (EAPCI). Eur Heart J 2008, 29:1463-1470.
• [5]Grube E, Laborde JC, Gerckens U, Felderhoff T, Sauren B, Buellesfeld L, Mueller R, Menichelli M, Schmidt T, Zickmann B, Iversen S, Stone GW: Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 2006, 114:1616-1624.
• [6]Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Munt BI, Buller CE, Pasupati S, Lichtenstein S: Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006, 113:842-850.
• [7]Zahn R, Gerckens U, Grube E, Linke A, Sievert H, Eggebrecht H, Hambrecht R, Sack S, Hauptmann KE, Richardt G, Figulla HR, Senges J, German Transcatheter Aortic Valve Intervention-Regsitry Investigators: Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. Eur Heart J 2011, 32:198-204.
• [8]Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L: Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999, 15:816-822.
• [9]Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Kucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, WIndecker S, Serruys PW: Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 2011, 32:205-217.
• [10]Lindroos M, Kupari M, Heikkilä , Tilvis R: Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993, 21:1220-1225.
• [11]Kolh P, Kerzmann A, Lahaye L, Gerard P, Limet R: Cardiac surgery in octogenarians: peri-operative outcome and long-term results. Eur Heart J 2001, 22:1235-1243.
• [12]Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskamp F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A, Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology, ESC Committee for Practice Guidelines: Guidelines on the management of valvular heart disease. The Task Force on the management of valvular heart diseases of the European Society of Cardiology. Eur Heart J 2007, 28:230-268.
• [13]Eltchaninoff H, Prat A, Gillard M, Lequerrier A, Blanchard D, Fournial G, Iung B, Donzeau-Gouge P, Tribouilloy C, Debrux JL, Pavie A, Gueret P, FRANCE Registry Investigators: Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J 2011, 32:191-197.
• [14]Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, Takkenberg JJ, David TE, Butcjardt EG, Adams DH, Shahian DM, Hagl S, Mayer JE, Lytle BW, Councils of the American Association for Thoracic Surgery, Society of Thoracic Surgeons; European Association for Cardio-Thoracic Surgery; Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity: Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 2008, 135:732-738.
• [15]Bridges CR, Edwards FH, Peterson ED, Coombs LP, Ferguson TB: Cardiac surgery in nonagenarians and centenarians. J Am Coll Surg 2003, 197:347-356.
• [16]Edwards MB, Taylor KM: Outcomes in nonagenarians after heart valve replacement operation. Ann Thorac Surg 2003, 75:830-834.
• [17]Bacchetta MD, Ko W, Girardi LN, Mack CA, Krieger KH, Isom OW, Lee LY: Outcomes of cardiac surgery in nonagenarians: a 10-year experience. Ann Thorac Surg 2003, 75:1215-1220.
• [18]Roberts WC, Ko JM, Matter GJ: Aortic valve replacement for aortic stenosis in nonagenarians. Am J Cardiol 2006, 98:1251-1253.
• [19]Weintraub WS, Clements SD, Ware J, Craver JM, Cohen CL, Jones EL, Guyton RA: Coronary artery surgery in octogenarians. Am J Cardiol 1991, 68:1530-1534.
• [20]Aregger F, Wenaweser P, Hellige GJ, Kadner A, Carrel T, S WI, Frey FJ: Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement. Nephrol Dial Transplant 2009, 24:2175-2179.
• [21]Dalrymple-Hay MJR, Alzetani A, Abdel-Nazar S, Haw M, Livesey S, Monro J: Cardiac surgery in the elderly. Eur J Cardiothoracic Surg 1999, 15:61-66.
• [22]Deiwick M, Tandler R, Möllhoff T, Kerber S, Rötker J, Roeder N, Scheld HH: Heart surgery in patients aged eighty years and above: determinants of morbidity and mortality. Thorac Cardiovasc Surg 1997, 45:119-126.
• [23]Yan TD, Cao C, Martens-Nielsen J, Pedang R, Nq M, Vallely MP, Bannon PG: Transcatheter aortic valve implantation for high-risk patients with severe aortic stenosis: A systematic review. J Thorac Cardiovasc Surg 2010, 139:1519-1528.
• [24]Levy Praschker BG, Leprince P, Bonnet N, Rama A, Bors V, Lievre L, Pavie A, Gandjbakhch I: Cardiac surgery in nonagenarians: hospital mortality and long-term follow-up. Interact Cardio Vasc Thorac Surg 2006, 5:696-699.